Table 1.
COPDGene study subjects.
| Demographics | N = 2590 Mean ± SD or distribution |
|---|---|
| Age, years | 65.5 ± 8.6 |
| Sex (Female/Male) | 1257/1333 |
| Race (Non-Hispanic White/African American) | 1940/650 |
| Smoking status (Current/Former) (n = 2580) | 909/1671 |
| Smoking History, pack-years (n = 2579) | 44.0 ± 24.0 |
| GOLD stage (n = 2541) | |
| 4 | 101 |
| 3 | 245 |
| 2 | 505 |
| 1 | 258 |
| Control | 1101 |
| PRISm * | 331 |
| FEV1% predicted (n = 2541) | 78.6 ± 24.2 |
| FEV1/FVC (n = 2540) | 0.68 ± 0.15 |
| Percent emphysema at -950HU (n = 2388) | 5.5 ± 9.2 |
| Body mass index kg/m2 (n = 2581) | 29.0 ± 6.3 |
| Airway wall thickness, segmental bronchi (n = 2385) | 1.03 ± 0.22 |
| Severe exacerbation in the year prior ** (no/yes) (n = 2581) | 2367/214 |
| Treated with chronic oral corticosteroids (no/yes) (n = 2538) | 2504/34 |
| Survival (alive/deceased) *** | 2431/159 |
| MMRC dyspnea score (n = 2581) | |
| 0 | 1316 |
| 1 | 344 |
| 2 | 315 |
| 3 | 424 |
| 4 | 182 |
| 6-min walk distance ft (n = 2539) | 1311 ± 442 |
| Comorbidity score **** (range 0 to 14) (n = 2581) | 2.97 ± 1.98 |
FEV1 = forced expiratory volume in 1 s; FVC = forced vital capacity; PRISm = Preserved Ratio Impaired Spirometry; mMRC = Modified Medical Research Council dyspnea score.
*PRISm (FEV1 < 80% predicted with FEV1/FVC ≥ 0.7)38.
**Emergency department or hospital admission.
***Survival status as of October 2018.
****Sum of comorbidities reported, considering Coronary Heart disease, Diabetes, Congestive heart failure, Stroke, Osteoarthritis, Osteoporosis, Hypertension, High cholesterol, Gastroesophageal reflux disease, Stomach ulcers, Obesity, Sleep apnea, Hay fever, Peripheral Vascular Disease53.